JP2008522632A - 骨再構築のプロセスに関与するポリヌクレオチド及びポリペプチド配列 - Google Patents

骨再構築のプロセスに関与するポリヌクレオチド及びポリペプチド配列 Download PDF

Info

Publication number
JP2008522632A
JP2008522632A JP2007545800A JP2007545800A JP2008522632A JP 2008522632 A JP2008522632 A JP 2008522632A JP 2007545800 A JP2007545800 A JP 2007545800A JP 2007545800 A JP2007545800 A JP 2007545800A JP 2008522632 A JP2008522632 A JP 2008522632A
Authority
JP
Japan
Prior art keywords
seq
polypeptide
polynucleotide
sequence
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007545800A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008522632A5 (https=
Inventor
ロイ・ラビンドラノース・スクナナン
ジル・ベルナール・トレンブレイ
マリオ・フィリヨン
Original Assignee
アレシア・バイオセラピューティクス・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレシア・バイオセラピューティクス・インコーポレーテッド filed Critical アレシア・バイオセラピューティクス・インコーポレーテッド
Publication of JP2008522632A publication Critical patent/JP2008522632A/ja
Publication of JP2008522632A5 publication Critical patent/JP2008522632A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Reproductive Health (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
JP2007545800A 2004-12-13 2005-12-13 骨再構築のプロセスに関与するポリヌクレオチド及びポリペプチド配列 Pending JP2008522632A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63498104P 2004-12-13 2004-12-13
PCT/CA2005/001917 WO2006063462A1 (en) 2004-12-13 2005-12-13 Polynucleotides and polypeptide sequences involved in the process of bone remodeling

Publications (2)

Publication Number Publication Date
JP2008522632A true JP2008522632A (ja) 2008-07-03
JP2008522632A5 JP2008522632A5 (https=) 2008-11-27

Family

ID=36587499

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007545800A Pending JP2008522632A (ja) 2004-12-13 2005-12-13 骨再構築のプロセスに関与するポリヌクレオチド及びポリペプチド配列

Country Status (6)

Country Link
US (3) US7947436B2 (https=)
EP (2) EP1831370A4 (https=)
JP (1) JP2008522632A (https=)
AU (1) AU2005316169B2 (https=)
CA (1) CA2590751A1 (https=)
WO (1) WO2006063462A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014230493A (ja) * 2013-05-28 2014-12-11 三菱レイヨン株式会社 間葉系幹細胞からの分化状態を識別する遺伝子群及び分化状態の評価方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2822302A1 (en) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Methods of impairing osteoclast differentiation
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
JP5451376B2 (ja) * 2007-03-15 2014-03-26 株式会社リバース・プロテオミクス研究所 血球系に特異的あるいは破骨細胞分化に特異的なバイオマーカー
US9493562B2 (en) 2012-07-19 2016-11-15 Alethia Biotherapeutics Inc. Anti-Siglec-15 antibodies
KR101463325B1 (ko) * 2013-01-14 2014-11-20 가톨릭대학교 산학협력단 HtrA2 단백질을 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 조성물
JP2021515588A (ja) 2018-01-26 2021-06-24 ケンブリッジ エンタープライズ リミティッド ペプチド交換蛋白質

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002027502A1 (en) * 2000-09-26 2002-04-04 Kabushiki Kaisha Toshiba Recording medium storing program for sending and receiving e-mail
JP2003334094A (ja) * 2002-03-15 2003-11-25 Sankyo Co Ltd 骨代謝異常の治療または予防剤の試験方法
WO2004076639A2 (en) * 2003-02-26 2004-09-10 Wyeth Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100202640B1 (ko) 1995-12-07 1999-06-15 구본준 씨알티의 잔류자속 제거방법
US5712127A (en) 1996-04-29 1998-01-27 Genescape Inc. Subtractive amplification
US5871917A (en) 1996-05-31 1999-02-16 North Shore University Hospital Research Corp. Identification of differentially methylated and mutated nucleic acids
US6617434B1 (en) * 1996-05-31 2003-09-09 North Shore Long Island Jewish Research Institute Identificiaton of differentially methylated and mutated nucleic acids
WO1998024886A1 (en) 1996-12-04 1998-06-11 Brigham And Women's Hospital, Inc. Mast cell protease that cleaves fibrinogen
WO1998036054A1 (en) 1997-02-13 1998-08-20 Amrad Operations Pty. Ltd. Novel molecules
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
US5981830A (en) 1997-05-30 1999-11-09 Schering Aktiengesellschaft Knockout mice and their progeny with a disrupted hepsin gene
NZ503343A (en) 1997-09-17 2002-09-27 Genentech Inc Secreted and transmembrane polypeptides and use to induce apoptosis of tumour cells
US20030054400A1 (en) 1997-09-17 2003-03-20 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20020192659A1 (en) 1997-09-17 2002-12-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7045603B2 (en) 1997-11-24 2006-05-16 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6203979B1 (en) 1998-01-16 2001-03-20 Incyte Pharmaceuticals, Inc. Human protease molecules
US7022821B1 (en) 1998-02-20 2006-04-04 O'brien Timothy J Antibody kit for the detection of TADG-15 protein
JP2002513554A (ja) 1998-05-05 2002-05-14 インサイト・ファーマスーティカルズ・インコーポレイテッド ヒト転写調節分子
US6998260B1 (en) 1998-05-15 2006-02-14 Promega Corporation Recombinant proteolytic tryptases, active site mutants thereof, and methods of making same
WO2000029448A2 (en) 1998-11-17 2000-05-25 Sagami Chemical Research Center Human proteins having hydrophobic domains and dnas encoding these proteins
US20050053983A1 (en) 1998-11-20 2005-03-10 Fuso Pharmaceutical Industries, Ltd. Novel serine protease BSSP4
WO2000031277A1 (en) 1998-11-20 2000-06-02 Fuso Pharmaceutical Industries, Ltd. Novel serine proteases bssp4
CA2353775A1 (en) 1998-12-22 2000-06-29 Genentech, Inc. Compositions and methods for the treatment of tumor
US7368527B2 (en) 1999-03-12 2008-05-06 Human Genome Sciences, Inc. HADDE71 polypeptides
CA2362670A1 (en) 1999-03-12 2000-09-14 Georgetown University Matriptase, a serine protease and its applications
US20070048818A1 (en) 1999-03-12 2007-03-01 Human Genome Sciences, Inc. Human secreted proteins
US6485957B1 (en) 1999-04-30 2002-11-26 Ortho-Mcneil Pharmaceutical, Inc. DNA encoding the human serine protease EOS
US6420157B1 (en) 1999-04-30 2002-07-16 Ortho-Mcneil Pharmaceutical, Inc. Zymogen activation system
US20030207348A1 (en) 1999-07-20 2003-11-06 Shimkets Richard A. Polypeptides and polynucleotides encoding same
EP1196576A2 (en) * 1999-07-20 2002-04-17 Curagen Corporation Secreted polypeptides and corresponding polynucleotides
US6514741B1 (en) 1999-08-18 2003-02-04 Zymogenetics, Inc. Tryptase-like polypeptide ztryp1
CA2379652A1 (en) 1999-08-18 2001-02-22 Zymogenetics, Inc. Tryptase-like polypeptide ztryp1
US6458564B1 (en) 1999-08-31 2002-10-01 Ortho-Mcneil Pharmaceutical, Inc. DNA encoding the human serine protease T
US6426199B1 (en) 1999-08-31 2002-07-30 Ortho-Mcneil Pharmaceutical, Inc. Dna
EP1087230A1 (en) * 1999-09-24 2001-03-28 Boehringer Ingelheim International GmbH Method for identifying compounds useful in the therapy of bone disorders
JP2003510074A (ja) 1999-09-27 2003-03-18 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ２６個のヒト分泌タンパク質
US20060084054A1 (en) 1999-09-27 2006-04-20 John Alsobrook Novel proteins and nucleic acids encoding same
US7030231B1 (en) 1999-09-30 2006-04-18 Catalyst Biosciences, Inc. Membrane type serine protease 1 (MT-SP1) and uses thereof
AU1205901A (en) 1999-10-14 2001-04-23 Board Of Trustees Of The University Of Arkansas, The Tumor antigen derived gene-16 (tadg-16): a novel extracellular serine protease and uses thereof
JP2003533174A (ja) 1999-11-17 2003-11-11 キュラジェン コーポレイション 新規なポリペプチドおよびこのポリペプチドをコードする核酸
EP1235838A4 (en) 1999-11-19 2003-09-10 Human Genome Sciences Inc 23 HUMAN SECRETED PROTEINS
JP2004500812A (ja) 1999-12-23 2004-01-15 インサイト・ゲノミックス・インコーポレイテッド プロテアーゼ
US20020042386A1 (en) 2000-01-31 2002-04-11 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20030077808A1 (en) 2000-01-31 2003-04-24 Rosen Craig A. Nucleic acids, proteins, and antibodies
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
US20040043930A1 (en) 2000-02-08 2004-03-04 Anderson David W. Novel proteins and nucleic acids encoding same
CA2400360A1 (en) 2000-02-15 2001-08-23 Curagen Corporation Polypeptides and nucleic acids encoding same
WO2001066747A2 (en) 2000-03-03 2001-09-13 Curagen Corporation Proteins named fctrx and nucleic acids encoding same
US20030065140A1 (en) 2000-04-03 2003-04-03 Vernet Corine A.M. Novel proteins and nucleic acids encoding same
AU2001274888A1 (en) 2000-05-19 2001-12-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2001098503A2 (en) 2000-06-21 2001-12-27 Bayer Aktiengesellschaft Regulation of human eosinophil serine protease 1-like enzyme
US7049420B2 (en) 2000-06-23 2006-05-23 Bayer Healthcare Ag Regulation of human prostasin-like serine protease
WO2001098467A2 (en) 2000-06-23 2001-12-27 Bayer Aktiengesellschaft Regulation of human prostasin-like serine protease
US20020064856A1 (en) 2000-06-26 2002-05-30 Gregory Plowman Novel proteases
US20030077647A1 (en) 2001-10-09 2003-04-24 Millennium Pharmaceuticals, Inc. 14081, a human trypsin-like serine protease family member and uses therefor
US20020045230A1 (en) 2000-08-14 2002-04-18 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20030228301A1 (en) 2000-10-24 2003-12-11 Li Li Novel human proteins, polynucleotides encoding them and methods of using the same
WO2002059315A2 (en) 2000-12-19 2002-08-01 Curagen Corporation Human nucleic acids and polypeptides and methods of use thereof
WO2002055704A2 (en) 2001-01-09 2002-07-18 Curagen Corp Proteins, polynucleotides encoding them and methods of using the same
WO2002068647A2 (en) 2001-01-16 2002-09-06 Curagen Corporation Proteins, polynucleotides encoding them and methods of using the same
WO2002098917A2 (en) 2001-02-12 2002-12-12 Curagen Corporation Human proteins and nucleic acids encoding same
EP1373565A2 (en) 2001-02-14 2004-01-02 Tularik Inc. Methods for the diagnosis and treatment of tumors employing the hepsin gene
US6482630B2 (en) 2001-03-29 2002-11-19 Applera Corporation Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
JP2004535169A (ja) 2001-04-06 2004-11-25 ランコート，デリック，イー． 着床セリンプロテアーゼ
US20060188903A1 (en) 2001-04-06 2006-08-24 Rancourt Derrick E Implantation serine proteinases
KR20040004642A (ko) 2001-05-23 2004-01-13 덴드레온 샌 디에고 엘엘씨 세포 표면 프로테아제에 의해 활성화되는 접합체 및 이의치료학적 용도
US20030068636A1 (en) 2001-06-21 2003-04-10 Millennium Pharmaceuticals, Inc. Compositions, kits and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer
WO2003009814A2 (en) 2001-07-25 2003-02-06 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
WO2003016475A2 (en) 2001-08-14 2003-02-27 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
WO2003063688A2 (en) 2002-01-25 2003-08-07 Incyte Corporation Protein modification and maintenance molecules
US20040126777A1 (en) 2002-01-28 2004-07-01 Bhatt Ramesh Rajani Lp mammalian proteins; related reagents
AU2003214920A1 (en) 2002-02-04 2003-09-02 Millennium Pharmaceuticals Inc. Methods and compositions for treating hematological disorders
US7160994B2 (en) 2002-03-28 2007-01-09 Trustees Of The University Of Pennsylvania Osteoclast-specific genes and proteins and uses thereof
EP1792912A3 (en) 2002-04-02 2007-08-29 Curagen Corporation Novel proteins and nucleic acids encoding same
US20040001801A1 (en) 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
US20030124706A1 (en) 2002-06-21 2003-07-03 Junming Yang Proteases
WO2004009803A2 (en) 2002-07-23 2004-01-29 Bayer Healthcare Ag Regulation of human hepsin
US6977170B2 (en) 2002-09-06 2005-12-20 Applera Corporation Isolated human hepsin/46 proteins, nucleic acid molecules encoding human hepsin/46 proteins, and uses thereof
AU2003289716A1 (en) 2002-09-12 2004-04-30 Incyte Corporation Molecules for diagnostics and therapeutics
AU2003279084A1 (en) 2002-09-25 2004-04-19 Genentech, Inc. Novel compositions and methods for the treatment of psoriasis
US20070224201A1 (en) 2002-10-02 2007-09-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2004033636A2 (en) 2002-10-04 2004-04-22 Incyte Corporation Protein modification and maintenance molecules
EP1558731A4 (en) 2002-10-04 2007-01-10 Schering Ag MODIFIED HEPSINE MOLECULES COMPRISING A SUBSTITUTION ACTIVATION SEQUENCE AND USES THEREOF
AU2002951912A0 (en) 2002-10-08 2002-10-24 Unisearch Limited Tryptase polypeptide and uses thereof
AU2003295511A1 (en) 2002-11-13 2004-06-03 Genentech, Inc. Methods and compositions for diagnosing dysplasia
US20040253606A1 (en) 2002-11-26 2004-12-16 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
WO2004053068A2 (en) 2002-12-05 2004-06-24 Incyte Corporation Protein modification and maintenance molecules
CA2941594C (en) 2002-12-20 2021-07-06 Celera Corporation Genetic polymorphisms of the protein receptor c (procr) associated with myocardial infarction, methods of detection and uses thereof
WO2004063355A2 (en) 2003-01-10 2004-07-29 Protein Design Labs, Inc. Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
WO2004086035A1 (en) 2003-03-28 2004-10-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with hepsin (hpn)
US20050255114A1 (en) 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
WO2004093804A2 (en) 2003-04-18 2004-11-04 Five Prime Therapeutics, Inc. Human polypeptides encoded by polynucleotides and methods of their use
EP1633850A4 (en) 2003-05-16 2007-04-04 Diadexus Inc OVR115 ANTIBODY COMPOSITIONS AND METHODS OF USE
WO2004106536A2 (en) 2003-05-28 2004-12-09 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with serine protease 8 (prss8)
CA2530605A1 (en) 2003-06-27 2005-05-26 Diadexus, Inc. Pro104 antibody compositions and methods of use
WO2005005647A2 (en) 2003-06-30 2005-01-20 Diadexus, Inc. Compositions, splice variants and methods relating to ovarian specific genes and proteins
US20040137623A1 (en) * 2003-09-17 2004-07-15 Isis Pharmaceuticals, Inc. Delivery of oligonucleotide compounds into osteoclasts and modulation of osteoclast differentiation
US20050176030A1 (en) 2003-10-28 2005-08-11 Li Gan Regulated nucleic acids in pathogenesis of Alzheimer's Disease
CA2547072C (en) 2003-11-26 2015-06-23 Applera Corporation Single nucleotide polymorphisms associated with cardiovascular disorders and statin response, methods of detection and uses thereof
US20050153333A1 (en) 2003-12-02 2005-07-14 Sooknanan Roy R. Selective terminal tagging of nucleic acids
WO2006131783A2 (en) 2004-01-27 2006-12-14 Compugen Usa, Inc. Polynucleotides, polypeptides, and diagnosing lung cancer
US7569662B2 (en) 2004-01-27 2009-08-04 Compugen Ltd Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of lung cancer
US20070253949A1 (en) 2004-02-03 2007-11-01 Stefan Golz Diagnostics and Therapeutics for Diseases Associated with Plasma Kallikrein (KLKB1)
US20060084066A1 (en) 2004-02-20 2006-04-20 Sah Dinah W Y Surrogate markers of neuropathic pain
WO2005119262A2 (en) 2004-05-27 2005-12-15 Galapagos N.V. Methods, compositions and compound assays for inhibiting amyloid-beta protein production
AU2005269463B2 (en) 2004-07-26 2011-08-18 Genentech, Inc. Methods and compositions for modulating hepatocyte growth factor activation
WO2006013016A2 (en) 2004-08-04 2006-02-09 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with eosinophil serine protease 1 (prss21)
WO2006013015A2 (en) 2004-08-04 2006-02-09 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with marapsin (mpn)
US7622265B2 (en) 2005-02-22 2009-11-24 Genentech, Inc. Methods and compositions for modulating prostasin
CA2625403A1 (en) 2005-10-17 2007-04-26 Institute For System Biology Tissue-and serum-derived glycoproteins and methods of their use
EP2433642B1 (en) 2005-10-21 2016-12-07 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
US7510850B2 (en) 2005-11-10 2009-03-31 Carnegie Institution Of Washington Isolation of the mitotic spindle matrix and its methods of use
EP1963534A2 (en) 2005-12-19 2008-09-03 Genizon Biosciences Inc. Genemap of the human gene associated with crohn's disease
WO2007140907A1 (en) 2006-06-07 2007-12-13 Bayer Healthcare Ag Use of serine endopeptidases 22 (prss22) as a therapeutic or diagnostic target
EP2030016B1 (en) 2006-06-22 2015-03-25 Genentech, Inc. Methods and compositions for modulating hepsin activation of urokinase-type plasminogen activator
WO2007149932A2 (en) 2006-06-22 2007-12-27 Genentech, Inc. Methods and compositions for targeting hepsin
US20100120627A1 (en) * 2006-08-02 2010-05-13 Abdelmajid Belouchi Genemap of the human genes associated with psoriasis
EP2520935A3 (en) 2006-08-09 2013-02-13 Homestead Clinical Corporation Organ-specific proteins and methods of their use
EP2091961A4 (en) 2006-11-22 2009-12-09 Univ Arkansas IMMUNOTHERAPY AGAINST CANCER WITH MULTIPPITOP-PEPTIDE-LOADED DENDRITIC CELLS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002027502A1 (en) * 2000-09-26 2002-04-04 Kabushiki Kaisha Toshiba Recording medium storing program for sending and receiving e-mail
JP2003334094A (ja) * 2002-03-15 2003-11-25 Sankyo Co Ltd 骨代謝異常の治療または予防剤の試験方法
WO2004076639A2 (en) * 2003-02-26 2004-09-10 Wyeth Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JPN6011027297; Ｊ　Ｂｏｎｅ　Ｍｉｎｅｒａｌ　Ｒｅｓ．，　１９［Ｓｕｐ１］　（２００４　Ｏｃｔ）　ｐ．Ｓ４１５ *
JPN6011027300; Ｊ　Ｂｉｏｌ　Ｃｈｅｍ．，　２７９　（２００４　Ａｐｒ）　ｐ．１３９８４-１３９９２． *
JPN6011027303; Ｇｅｎｅ　Ｃｅｌｌ．，　３　（１９９８）　ｐ．４５９-４７５． *
JPN6011027305; 実験医学，　１３［４］　（１９９５）　ｐ．４６-５２． *
JPN6012025231; Ｃａｎｃｅｒ　Ｒｅｓ．，　５９［１３］　（１９９９）　ｐ．３２１５-２１． *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014230493A (ja) * 2013-05-28 2014-12-11 三菱レイヨン株式会社 間葉系幹細胞からの分化状態を識別する遺伝子群及び分化状態の評価方法

Also Published As

Publication number Publication date
US20120308561A1 (en) 2012-12-06
CA2590751A1 (en) 2006-06-22
EP2275547B1 (en) 2014-03-05
WO2006063462A9 (en) 2007-07-26
AU2005316169A1 (en) 2006-06-22
EP1831370A1 (en) 2007-09-12
US20110293604A1 (en) 2011-12-01
US7947436B2 (en) 2011-05-24
US20090004206A1 (en) 2009-01-01
WO2006063462A1 (en) 2006-06-22
EP1831370A4 (en) 2009-08-12
US8444975B2 (en) 2013-05-21
EP2275547A2 (en) 2011-01-19
EP2275547A3 (en) 2011-05-04
AU2005316169B2 (en) 2011-11-17

Similar Documents

Publication Publication Date Title
JP6224182B2 (ja) 骨リモデリングのプロセスと関係があるポリヌクレオチドおよびポリペプチド配列
USRE47672E1 (en) Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
DK2081586T3 (en) RSPONDINES AS MODULATORS OF ANGIOGENESE AND VASCULOGENESES
US8444975B2 (en) Method for inhibiting bone resorption
JP2003334088A (ja) ヒト由来の新規Ｋｌｏｔｈｏ様タンパク質及びその遺伝子
AU2014200123B2 (en) Polynucleotides and polypeptide sequences involved in the process of bone remodeling
JP2002355063A (ja) 新規疾患関連遺伝子およびその用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081002

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081002

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110531

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110811

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120522

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120731

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120807

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130312